Medicine · 6 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result is that VV116 showed a favorable safety profile with no serious adverse events and demonstrated non-inferiority to nirmatrelvir-ritonavir in alleviating major symptoms, but evidence is limited to younger, non-severe patients.
The methods included a comprehensive literature search across PubMed, Scopus, and Google Scholar. The central results indicated no serious adverse events were reported in VV116 groups, which showed a 2.57-day faster time to viral shedding compared to controls and were non-inferior to nirmatrelvir-ritonavir in alleviating major symptoms. Therefore, the evidence does not support conclusions about efficacy or safety in elderly or critically ill populations.
